The changes in the levels of Tau N368 CSF markers track the longitudinal changes in tracer uptake better than changes in P-tau181p and T-Tau levels and improve concordance with dichotomized regional [18F]THK5317 measures in AD patients79. The gene discussed is MAPT; the disease is Alzheimer disease.